Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
Status:
Completed
Trial end date:
2015-06-18
Target enrollment:
Participant gender:
Summary
The objectives of the study are:
- To evaluate the safety and tolerability of single and multiple oral doses of VP 20629 in
subjects with Friedreich's ataxia (FA). [Primary]
- To characterize the pharmacokinetics of VP 20629 by investigation of the plasma
concentration-time profile following single and multiple oral doses in subjects with FA.
[Secondary]
- To investigate the pharmacodynamic effects of VP 20629 on plasma 8-isoprostane and
malondialdehyde and urinary 8-hydroxydeoxyguanosine concentrations following multiple
oral doses in subjects with FA. [Exploratory]